Membership: Join my YouTube channel membership and unlock exclusive perks! As a member, you'll get early access to videos to stay ahead with the latest content before anyone else. Investor tier members get access to my spreadsheets, and VIP discord members get access to our private discord community
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 18 Feb 2026, 22:41 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:24 UTC

AI-generated source summary
HIMS stock has experienced a significant decline of over 46% in the last month, following a patent infringement lawsuit filed by Novo Nordisk (NVO) targeting HIMS' semaglutide offerings. This legal action is compounded by an FDA crackdown on unapproved GLP-1 compounding, forcing HIMS to abandon its $49 oral Wegovy alternative. Novo Nordisk, which recently received approval for its weight loss pill and sells it for $149 monthly, is taking legal action against HIMS, alleging patent infringement for selling compounded versions of their treatments at a lower price. This has led to a decline in Novo Nordisk's market share, with an estimated 1 million people using HIMS' compounded knockoff versions. Novo Nordisk is not happy about these developments, as HIMS' actions are undercutting their sales and impacting their market share after billions spent on R&D and regulatory approval.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
